AIMC Topic: Lenalidomide

Clear Filters Showing 1 to 4 of 4 articles

Dose reduction and toxicity of lenalidomide-dexamethasone in multiple myeloma: A machine-learning prediction model.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners Sep 6, 2023
PURPOSE: Lenalidomide remains an effective drug for multiple myeloma, but it is often associated with adverse events and requires dose adjustments. The objective of this study was to propose a model for predicting whether a patient would require dose...
Male Middle Aged Aged Aged, 80 and over Dexamethasone Multiple Myeloma Lenalidomide Antineoplastic Combined Chemotherapy Protocols Dose-Response Relationship, Drug Humans Machine Learning Retrospective Studies Female
View on PubMed DOI

Recent advances in drug repurposing using machine learning.

Current opinion in chemical biology Jul 16, 2021
Drug repurposing aims to find new uses for already existing and approved drugs. We now provide a brief overview of recent developments in drug repurposing using machine learning alongside other computational approaches for comparison. We also highlig...
Neuroprotective Agents Drug Repositioning Antiviral Agents Computational Biology COVID-19 Drug Treatment Piperidines Protein Kinase Inhibitors Piperazines Alzheimer Disease Humans Machine Learning Neoplasms Antineoplastic Agents Hydroxychloroquine Lenalidomide Clemastine Dipyridamole
View on PubMed DOI

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.

Clinical lymphoma, myeloma & leukemia Dec 30, 2017
BACKGROUND: The phase III MDS-005 study compared lenalidomide versus placebo in red blood cell transfusion-dependent (RBC-TD) patients with lower-risk non-del(5q) myelodysplastic syndromes (MDS), ineligible/refractory to erythropoiesis-stimulating ag...
Surveys and Questionnaires Angiogenesis Inhibitors Quality of Life Disease Progression Myelodysplastic Syndromes Chromosome Deletion Aged, 80 and over Risk Factors Humans Adult Chromosomes, Human, Pair 5 Aged Male Female Lenalidomide Double-Blind Method Middle Aged Outcome Assessment, Health Care
View on PubMed DOI

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.

Clinical lymphoma, myeloma & leukemia Dec 21, 2015
INTRODUCTION: The present study evaluated the pharmacokinetics and safety of elotuzumab, a humanized IgG1 monoclonal antibody against signaling lymphocyte activation molecule-F7, combined with lenalidomide and dexamethasone, in patients with multiple...
Cytogenetic Analysis Retreatment Aged, 80 and over Multiple Myeloma Adult Lenalidomide Male Middle Aged Treatment Outcome Female Humans Kidney Function Tests Aged Neoplasm Staging Severity of Illness Index Antibodies, Monoclonal, Humanized Thalidomide Dexamethasone Antineoplastic Combined Chemotherapy Protocols Kidney Diseases
View on PubMed DOI
Popular Topics
Recent Journals